PolyPid Ltd. (NASDAQ:PYPD) Short Interest Down 45.0% in May

PolyPid Ltd. (NASDAQ:PYPD – Get Rating) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 114,900 shares, a decline of 45.0% from the April 30th total of 209,000 shares. Based on an average daily volume of 98,800 shares, the days-to-cover ratio is currently 1.2 days.

PolyPid Stock Performance

Shares of PYPD stock opened at $0.38 on Friday. The firm has a fifty day simple moving average of $0.42 and a two-hundred day simple moving average of $0.64. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.75 and a current ratio of 2.75. PolyPid has a 12 month low of $0.33 and a 12 month high of $6.90.

PolyPid (NASDAQ:PYPD – Get Rating) last announced its quarterly earnings results on Wednesday, May 10th. The company reported ($0.28) EPS for the quarter. Analysts expect that PolyPid will post -1.05 earnings per share for the current fiscal year.

Institutional Trading of PolyPid

Several institutional investors have recently made changes to their positions in the company. Boothbay Fund Management LLC grew its stake in shares of PolyPid by 514.5% in the 1st quarter. Boothbay Fund Management LLC now owns 122,898 shares of the company’s stock worth $57,000 after acquiring an additional 102,898 shares in the last quarter. UBS Group AG grew its stake in shares of PolyPid by 29.9% in the 1st quarter. UBS Group AG now owns 285,399 shares of the company’s stock worth $1,558,000 after acquiring an additional 65,746 shares in the last quarter. Silverarc Capital Management LLC grew its stake in shares of PolyPid by 1.2% in the 1st quarter. Silverarc Capital Management LLC now owns 218,175 shares of the company’s stock worth $1,191,000 after acquiring an additional 2,555 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of PolyPid in the 1st quarter worth $72,000. Finally, Raymond James Financial Services Advisors Inc. grew its stake in shares of PolyPid by 83.3% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 52,251 shares of the company’s stock worth $285,000 after acquiring an additional 23,752 shares in the last quarter. Institutional investors own 2.48% of the company’s stock.

About PolyPid

(Get Rating)

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.